

# DIN EN ISO 14155:2026-08 (E)

## Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2026)

---

| <b>Contents</b>                                                                                           | <b>Page</b> |
|-----------------------------------------------------------------------------------------------------------|-------------|
| <b>Foreword</b> .....                                                                                     | <b>vi</b>   |
| <b>Introduction</b> .....                                                                                 | <b>viii</b> |
| <b>1 Scope</b> .....                                                                                      | <b>1</b>    |
| <b>2 Normative references</b> .....                                                                       | <b>1</b>    |
| <b>3 Terms and definitions</b> .....                                                                      | <b>1</b>    |
| <b>4 Summary of good clinical practice principles</b> .....                                               | <b>9</b>    |
| <b>5 Ethical considerations</b> .....                                                                     | <b>10</b>   |
| 5.1 General.....                                                                                          | 10          |
| 5.2 Improper influence or inducement.....                                                                 | 10          |
| 5.3 Compensation and additional health care .....                                                         | 10          |
| 5.4 Registration in publicly accessible database .....                                                    | 11          |
| 5.5 Responsibilities.....                                                                                 | 11          |
| 5.6 Communication with the ethics committee .....                                                         | 11          |
| 5.6.1 General .....                                                                                       | 11          |
| 5.6.2 Initial EC submission .....                                                                         | 11          |
| 5.6.3 Information to be obtained from the EC .....                                                        | 12          |
| 5.6.4 Continuing communication with the EC.....                                                           | 12          |
| 5.6.5 Continuing information to be obtained from the EC.....                                              | 12          |
| 5.7 Vulnerable populations.....                                                                           | 12          |
| 5.8 Informed consent.....                                                                                 | 13          |
| 5.8.1 General .....                                                                                       | 13          |
| 5.8.2 Process of obtaining informed consent .....                                                         | 13          |
| 5.8.3 Special circumstances for informed consent.....                                                     | 14          |
| 5.8.4 Information to be provided to the subject .....                                                     | 15          |
| 5.8.5 Informed consent signature.....                                                                     | 16          |
| 5.8.6 New information.....                                                                                | 17          |
| <b>6 Clinical investigation planning</b> .....                                                            | <b>17</b>   |
| 6.1 General.....                                                                                          | 17          |
| 6.2 Risk management.....                                                                                  | 17          |
| 6.2.1 General.....                                                                                        | 17          |
| 6.2.2 Risks related to the use of the investigational device and their disclosure.....                    | 18          |
| 6.2.3 Risks related to clinical procedures required by the CIP outside routine clinical<br>practice ..... | 18          |
| 6.2.4 Risks related to the clinical investigation process .....                                           | 19          |
| 6.3 Justification for the design of the clinical investigation .....                                      | 19          |
| 6.4 Clinical investigation plan.....                                                                      | 19          |
| 6.5 Investigator's brochure.....                                                                          | 20          |
| 6.6 Case report forms .....                                                                               | 20          |
| 6.7 Monitoring plan .....                                                                                 | 20          |
| 6.8 Investigation site selection.....                                                                     | 21          |
| 6.9 Agreement(s).....                                                                                     | 22          |
| 6.10 Labelling.....                                                                                       | 22          |
| 6.11 Data monitoring committee .....                                                                      | 22          |
| 6.12 Clinical events committee .....                                                                      | 22          |
| <b>7 Clinical investigation conduct</b> .....                                                             | <b>23</b>   |
| 7.1 General.....                                                                                          | 23          |
| 7.2 Investigation site initiation.....                                                                    | 23          |
| 7.3 Investigation site monitoring.....                                                                    | 23          |

|           |                                                                                                                   |           |
|-----------|-------------------------------------------------------------------------------------------------------------------|-----------|
| 7.4       | Adverse events and device deficiencies .....                                                                      | 23        |
| 7.4.1     | Signals requiring immediate action .....                                                                          | 23        |
| 7.4.2     | Adverse events .....                                                                                              | 23        |
| 7.4.3     | Device deficiencies .....                                                                                         | 24        |
| 7.4.4     | Risk assessment process for potentially unacceptable risks related to the use of the investigational device ..... | 24        |
| 7.4.5     | Management of risks related to clinical procedures required by the CIP outside routine clinical practice .....    | 25        |
| 7.5       | Clinical investigation documents and documentation .....                                                          | 25        |
| 7.5.1     | Amendments .....                                                                                                  | 25        |
| 7.5.2     | Subject identification log .....                                                                                  | 25        |
| 7.5.3     | Source documents .....                                                                                            | 26        |
| 7.6       | Additional members of the investigation site team .....                                                           | 26        |
| 7.7       | Subject privacy and confidentiality of data .....                                                                 | 26        |
| 7.8       | Document and data control .....                                                                                   | 26        |
| 7.8.1     | Traceability of documents and data .....                                                                          | 26        |
| 7.8.2     | Recording of data .....                                                                                           | 26        |
| 7.8.3     | Electronic clinical data systems .....                                                                            | 27        |
| 7.9       | Investigational device accountability .....                                                                       | 28        |
| 7.10      | Accounting for subjects .....                                                                                     | 28        |
| 7.11      | Auditing .....                                                                                                    | 28        |
| <b>8</b>  | <b>Suspension, termination and close-out of the clinical investigation .....</b>                                  | <b>29</b> |
| 8.1       | Completion of the clinical investigation .....                                                                    | 29        |
| 8.2       | Suspension or premature termination of the clinical investigation .....                                           | 29        |
| 8.2.1     | General .....                                                                                                     | 29        |
| 8.2.2     | Procedure for suspension .....                                                                                    | 29        |
| 8.2.3     | Procedure for premature termination .....                                                                         | 30        |
| 8.2.4     | Procedure for resuming the clinical investigation after suspension .....                                          | 30        |
| 8.3       | Routine close-out .....                                                                                           | 31        |
| 8.4       | Clinical investigation report .....                                                                               | 31        |
| 8.5       | Risk assessment and conclusions .....                                                                             | 32        |
| 8.6       | Document retention .....                                                                                          | 32        |
| <b>9</b>  | <b>Responsibilities of the sponsor .....</b>                                                                      | <b>32</b> |
| 9.1       | Clinical quality management .....                                                                                 | 32        |
| 9.2       | Clinical investigation planning and conduct .....                                                                 | 33        |
| 9.2.1     | Selection and training of clinical personnel .....                                                                | 33        |
| 9.2.2     | Preparation of documents and materials .....                                                                      | 34        |
| 9.2.3     | Conduct of clinical investigation .....                                                                           | 34        |
| 9.2.4     | Monitoring .....                                                                                                  | 35        |
| 9.2.5     | Safety evaluation and reporting .....                                                                             | 37        |
| 9.2.6     | Clinical investigation close-out .....                                                                            | 38        |
| 9.3       | Outsourcing of duties and functions .....                                                                         | 38        |
| 9.4       | Communication with regulatory authorities .....                                                                   | 39        |
| <b>10</b> | <b>Responsibilities of the principal investigator .....</b>                                                       | <b>39</b> |
| 10.1      | General .....                                                                                                     | 39        |
| 10.2      | Qualification of the principal investigator .....                                                                 | 39        |
| 10.3      | Qualification of investigation site .....                                                                         | 39        |
| 10.4      | Communication with the EC .....                                                                                   | 40        |
| 10.5      | Informed consent process .....                                                                                    | 40        |
| 10.6      | Compliance with the CIP .....                                                                                     | 40        |
| 10.7      | Medical care of subjects .....                                                                                    | 41        |
| 10.8      | Safety reporting .....                                                                                            | 42        |
|           | <b>Annex A (normative) Clinical investigation plan .....</b>                                                      | <b>43</b> |
|           | <b>Annex B (normative) Investigator's brochure .....</b>                                                          | <b>51</b> |

|                                                                                           |           |
|-------------------------------------------------------------------------------------------|-----------|
| <b>Annex C (informative) Case report forms .....</b>                                      | <b>54</b> |
| <b>Annex D (normative) Clinical investigation report.....</b>                             | <b>56</b> |
| <b>Annex E (informative) Essential clinical investigation documents .....</b>             | <b>61</b> |
| <b>Annex F (informative) Adverse event categorization.....</b>                            | <b>67</b> |
| <b>Annex G (informative) EC responsibilities.....</b>                                     | <b>69</b> |
| <b>Annex H (informative) Application of ISO 14971 during clinical investigations.....</b> | <b>73</b> |
| <b>Annex I (informative) Clinical development stages.....</b>                             | <b>74</b> |
| <b>Annex J (informative) Clinical investigation audits.....</b>                           | <b>79</b> |
| <b>Annex K (informative) Clinical investigation design considerations.....</b>            | <b>82</b> |
| <b>Bibliography.....</b>                                                                  | <b>84</b> |